Postoperative peak serum C-reactive protein is a predictor of outcome following liver transplantation for hepatocellular carcinoma

References

• An HJ, Jang JW, Bae SH, et al. (2012). Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 18:1406–14
   PubMed Web of Science ®Google Scholar
• Bertuzzo VR, Cescon M, Ravaioli M, et al. (2011). Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 91:1279–85
   PubMed Web of Science ®Google Scholar
• Cescon M, Bertuzzo VR, Ercolani G, et al. (2013). Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol 19:9174–82
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature 420:860–7
   PubMed Web of Science ®Google Scholar
• Croome KP, Wall W, Chandok N, et al. (2013). Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl 19:1214–23
   PubMed Web of Science ®Google Scholar
• Diepenhorst GM, de Graaf W, Niessen HW, et al. (2014). Immunoglobulin M, C-reactive protein and complement activation in rat hepatic ischemia-reperfusion injury. Eur Surg Res 52:50–62
   PubMed Web of Science ®Google Scholar
• Earl TM, Chapman WC. (2013). Transplantation for hepatocellular carcinoma: the North American experience. Recent Results Cancer Res 190:145–64
   PubMedGoogle Scholar
• Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. (2004). C-reactive protein and the risk of incident colorectal cancer. JAMA 291:585–90
   PubMed Web of Science ®Google Scholar
• Fang S, Wang Y, Sui D, et al. (2015). C-reactive protein as a marker of melanoma progression. J Clin Oncol 33:1389–96
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Ikeda Y, Korenaga D, et al. (2005). The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103:1856–64
   PubMed Web of Science ®Google Scholar
• Huang Y, Feng JF, Liu JS, Chen QX. (2015). Prognostic role of serum C-reactive protein in esophageal cancer: a systematic review and meta-analysis. Ther Clin Risk Manag 11:89–94
   PubMed Web of Science ®Google Scholar
• Jang JW, Oh BS, Kwon JH, et al. (2012). Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 60:686–93
   PubMed Web of Science ®Google Scholar
• Jonas S, Bechstein WO, Steinmüller T, et al. (2001). Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33:1080–6
   PubMed Web of Science ®Google Scholar
• Jun CH, Ki HS, Lee KH, et al. (2013). Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol 19:70–7
   PubMedGoogle Scholar
• Karakiewicz PI, Hutterer GC, Trinh QD, et al. (2007). C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110:1241–7
   PubMed Web of Science ®Google Scholar
• Klune JR, Tsung A. (2010). Molecular biology of liver ischemia/reperfusion injury: established mechanisms and recent advancements. Surg Clin North Am 90:665–77
   PubMed Web of Science ®Google Scholar
• Kornberg A. (2014). Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol 2014:Article ID 706945
   Google Scholar
• Kornberg A, Witt U, Kornberg J, et al. (2015). Extended ischemia times promote risk of HCC recurrence in liver transplant patients. Dig Dis Sci 60:2832–39
   PubMed Web of Science ®Google Scholar
• Kumaran V. (2014). Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol 4:S97–103
   PubMedGoogle Scholar
• Lo CM, Fan ST, Liu CL, et al. (2007). Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 94:78–86
   PubMed Web of Science ®Google Scholar
• Maggs JR, Suddle AR, Aluvihare V, Heneghan MA. (2012). Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 35:1113–34
   PubMed Web of Science ®Google Scholar
• Man K, Ng KT, Lo CM, et al. (2007). Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases – activation of cell invasion and migration pathways. Liver Transpl 13:1669–77
   PubMed Web of Science ®Google Scholar
• Man K, Lo CM, Xiao JW, et al. (2008). The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg 247:1049–57
   PubMed Web of Science ®Google Scholar
• Mathur A, Franco ES, Leone JP, et al. (2013). Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford) 15:504–10
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–9
   PubMed Web of Science ®Google Scholar
• Na GH, Kim DG, Han JH, et al. (2014). Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation. World J Gastroenterol 20:6594–601
   PubMed Web of Science ®Google Scholar
• Nagai S, Yoshida A, Facciuto M, et al. (2015). Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology 61:895–904
   PubMed Web of Science ®Google Scholar
• Nastos C, Kalimeris K, Papoutsidakis N, et al. (2014). Global consequences of liver ischemia/reperfusion injury. Oxid Med Cell Longev 2014:906965. DOI: 10.1155/2014/906965
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Arimoto A, Wakasa T, et al. (2013). Pre-treatment C-reactive protein as a prognostic factor for recurrence after surgical resection of hepatocellular carcinoma. Anticancer Res 33:1181–8
   PubMed Web of Science ®Google Scholar
• Nozoe T, Matsumata T, Kitamura M, Sugimachi K. (1998). Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176:335–8
   PubMed Web of Science ®Google Scholar
• Orci LA, Lacotte S, Oldani G, et al. (2014). The role of hepatic ischemia-reperfusion injury and liver parenchymal quality on cancer recurrence. Dig Dis Sci 59:2058–68
   PubMed Web of Science ®Google Scholar
• Salazar J, Martínez MS, Chávez M, et al. (2014). C-reactive protein: clinical and epidemiological perspectives. Cardiol Res Pract 2014:605810. DOI: 10.1155/2014/605810
   PubMedGoogle Scholar
• Shiba H, Furukawa K, Fujiwara Y, et al. (2013). Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma. Anticancer Res 33:705–9
   PubMed Web of Science ®Google Scholar
• Shindoh J, Sugawara Y, Nagata R, et al. (2014). Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma. Transpl Int 27:391–8
   PubMed Web of Science ®Google Scholar
• Sieghart W, Pinter M, Hucke F, et al. (2013). Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology 57:2224–34
   PubMed Web of Science ®Google Scholar
• Takada Y, Tohyama T, Watanabe J. (2015). Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepatobiliary Pancreat Sci 22:279–86
   PubMed Web of Science ®Google Scholar
• Tilg H, Nordberg J, Vogel W, et al. (1992). Circulating serum levels of interleukin 6 and C-reactive protein after liver transplantation. Transplantation 54:142–6
   PubMed Web of Science ®Google Scholar
• Toso C, Mentha G, Majno P. (2011). Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 11:2031–5
   PubMed Web of Science ®Google Scholar
• Vagefi PA, Dodge JL, Yao FY, Roberts JP. (2015). Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 21:187–94
   PubMed Web of Science ®Google Scholar
• van der Bilt JD, Kranenburg O, Nijkamp MW, et al. (2005). Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 42:165–75
   PubMed Web of Science ®Google Scholar
• Wang CY, Hsieh MJ, Chiu YC, et al. (2009). Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 92:270–5
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shi ZL, Yang X, Yin ZF. (2014). Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis. World J Gastroenterol 20:142–7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Cao L, et al. (2012). Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol 39:449–60
   PubMed Web of Science ®Google Scholar
• Zheng Z, Zhou L, Gao S, et al. (2013). Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci 10:653–64
   PubMed Web of Science ®Google Scholar